344 related articles for article (PubMed ID: 28672102)
21. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
Front Immunol; 2020; 11():560074. PubMed ID: 33304345
[TBL] [Abstract][Full Text] [Related]
22. Distinct nuclear receptor expression in stroma adjacent to breast tumors.
Knower KC; Chand AL; Eriksson N; Takagi K; Miki Y; Sasano H; Visvader JE; Lindeman GJ; Funder JW; Fuller PJ; Simpson ER; Tilley WD; Leedman PJ; Graham J; Muscat GE; Clarke CL; Clyne CD
Breast Cancer Res Treat; 2013 Nov; 142(1):211-23. PubMed ID: 24122391
[TBL] [Abstract][Full Text] [Related]
23. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
24. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
25. Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer.
Callari M; Musella V; Di Buduo E; Sensi M; Miodini P; Dugo M; Orlandi R; Agresti R; Paolini B; Carcangiu ML; Cappelletti V; Daidone MG
Mol Oncol; 2014 Oct; 8(7):1278-89. PubMed ID: 24853384
[TBL] [Abstract][Full Text] [Related]
26. Gene expression patterns associated with p53 status in breast cancer.
Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM
BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
28. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
29. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS;
Ann Oncol; 2015 Jan; 26(1):81-88. PubMed ID: 25361981
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling.
Frings O; Augsten M; Tobin NP; Carlson J; Paulsson J; Pena C; Olsson E; Veerla S; Bergh J; Ostman A; Sonnhammer EL
Am J Pathol; 2013 Jun; 182(6):2037-47. PubMed ID: 23583284
[TBL] [Abstract][Full Text] [Related]
31. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.
Bradford JR; Wappett M; Beran G; Logie A; Delpuech O; Brown H; Boros J; Camp NJ; McEwen R; Mazzola AM; D'Cruz C; Barry ST
Oncotarget; 2016 Apr; 7(15):20773-87. PubMed ID: 26980748
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated stromal cells as key contributors to the tumor microenvironment.
Bussard KM; Mutkus L; Stumpf K; Gomez-Manzano C; Marini FC
Breast Cancer Res; 2016 Aug; 18(1):84. PubMed ID: 27515302
[TBL] [Abstract][Full Text] [Related]
33. MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer.
Choschzick M; Heilenkötter U; Lebeau A; Jaenicke F; Terracciano L; Bokemeyer C; Sauter G; Simon R
Cancer Biomark; 2010-2011; 8(2):53-60. PubMed ID: 21896991
[TBL] [Abstract][Full Text] [Related]
34. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
35. MMP1 and MMP11 Expression in Peripheral Blood Mononuclear Cells upon Their Interaction with Breast Cancer Cells and Fibroblasts.
Eiro N; Cid S; Aguado N; Fraile M; de Pablo N; Fernández B; Domínguez F; González LO; Vizoso FJ
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396463
[TBL] [Abstract][Full Text] [Related]
36. Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity.
Giordano C; Chemi F; Panza S; Barone I; Bonofiglio D; Lanzino M; Cordella A; Campana A; Hashim A; Rizza P; Leggio A; Győrffy B; Simões BM; Clarke RB; Weisz A; Catalano S; Andò S
Oncotarget; 2016 Jan; 7(2):1262-75. PubMed ID: 26556856
[TBL] [Abstract][Full Text] [Related]
37. Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Joo EH; Kim S; Park D; Lee T; Park WY; Han KY; Lee JE
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892065
[TBL] [Abstract][Full Text] [Related]
38. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
39. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
40. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
